Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Sep 18;5(9):e008953.
doi: 10.1136/bmjopen-2015-008953.

Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial

Julia Wade  1 , Peter N Holding  2 , Susan Bonnington  2 , Leila Rooshenas  1 , J Athene Lane  1 , C Elizabeth Salter  1 , Kate Tilling  1 , Mark J Speakman  3 , Simon F Brewster  4 , Simon Evans  5 , David E Neal  6 , Freddie C Hamdy  2 , Jenny L Donovan  7 ; ProtecT Study Group
Collaborators, Affiliations
Randomized Controlled Trial

Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial

Julia Wade et al. BMJ Open. .

Abstract

Objectives: To develop a nurse-led, urologist-supported model of care for men managed by active surveillance or active monitoring (AS/AM) for localised prostate cancer and provide a formative evaluation of its acceptability to patients, clinicians and nurses. Nurse-led care, comprising an explicit nurse-led protocol with support from urologists, was developed as part of the AM arm of the Prostate testing for cancer and Treatment (ProtecT) trial.

Design: Interviews and questionnaire surveys of clinicians, nurses and patients assessed acceptability.

Setting: Nurse-led clinics were established in 9 centres in the ProtecT trial and compared with 3 non-ProtecT urology centres elsewhere in UK.

Participants: Within ProtecT, 22 men receiving AM nurse-led care were interviewed about experiences of care; 11 urologists and 23 research nurses delivering ProtecT trial care completed a questionnaire about its acceptability; 20 men managed in urology clinics elsewhere in the UK were interviewed about models of AS/AM care; 12 urologists and three specialist nurses working in these clinics were also interviewed about management of AS/AM.

Results: Nurse-led care was commended by ProtecT trial participants, who valued the flexibility, accessibility and continuity of the service and felt confident about the quality of care. ProtecT consultant urologists and nurses also rated it highly, identifying continuity of care and resource savings as key attributes. Clinicians and patients outside the ProtecT trial believed that nurse-led care could relieve pressure on urology clinics without compromising patient care.

Conclusions: The ProtecT AM nurse-led model of care was acceptable to men with localised prostate cancer and clinical specialists in urology. The protocol is available for implementation; we aim to evaluate its impact on routine clinical practice.

Trial registration numbers: NCT02044172; ISRCTN20141297.

Keywords: UROLOGY.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Topics covered in in-depth interviews (AM, active monitoring; AS, active surveillance).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. National Collaborating Centre for Cancer. Prostate Cancer: Diagnosis and Treatment, Clinical Guideline, January 2014, commissioned by the National Institute for Health and Care Excellence.
    1. Maddams J, Utley M, Møller H. Projections of cancer prevalence in the United Kingdom, 2010–2040. Br J Cancer 2012;107:1195–202. 10.1038/bjc.2012.366 - DOI - PMC - PubMed
    1. Huang GJ, Sadetsky N, Penson DF. Health related quality of life for men treated for localized prostate cancer with long-term follow up. J Urol 2010;183:206–12. - PMC - PubMed
    1. Dall'Era MA, Albertsen PC, Bangma C et al. . Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012;62:976–83. 10.1016/j.eururo.2012.05.072 - DOI - PubMed
    1. Dahabreh IJ, Chung M, Balk EM et al. . Active surveillance in men with localized prostate cancer: a systematic review. Ann Intern Med 2012;156:582–90. 10.7326/0003-4819-156-8-201204170-00009 - DOI - PubMed

Publication types

MeSH terms

Substances

Associated data